Quest Diagnostics To Acquire PathAI Diagnostics To Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements With PathAI
3BL Media
MAY 6, 2024
PathAI will continue to support its biopharmaceutical clients with end-to-end clinical trial services capabilities at its biopharma lab, which is separate and distinct from the diagnostic laboratory business. SECAUCUS, N.J. The transaction is expected to be completed in the second quarter of 2024.
Let's personalize your content